Annual Total Expenses
$28.06 B
+$2.33 B+9.07%
March 31, 2024
Summary
- As of February 7, 2025, TAK annual total expenses is $28.06 billion, with the most recent change of +$2.33 billion (+9.07%) on March 31, 2024.
- During the last 3 years, TAK annual total expenses has risen by +$1.65 billion (+6.26%).
- TAK annual total expenses is now at all-time high.
Performance
TAK Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Expenses
$7.65 B
+$1.57 B+25.89%
December 1, 2024
Summary
- As of February 7, 2025, TAK quarterly total expenses is $7.65 billion, with the most recent change of +$1.57 billion (+25.89%) on December 1, 2024.
- Over the past year, TAK quarterly total expenses has increased by +$1.57 billion (+25.89%).
- TAK quarterly total expenses is now -3.67% below its all-time high of $7.94 billion, reached on December 31, 2023.
Performance
TAK Quarterly Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Expenses Formula
Total Expenses = Cost of Goods Sold + Operating Expenses + Non Operating Expenses
TAK Total Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +9.1% | +25.9% |
| 3 y3 years | +6.3% | +25.8% |
| 5 y5 years | +63.3% | +13.8% |
TAK Total Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +9.1% | -3.7% | +25.9% |
| 5 y | 5-year | at high | +63.3% | -3.7% | +29.7% |
| alltime | all time | at high | +384.1% | -3.7% | +475.7% |
Takeda Pharmaceutical Company Limited Total Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | - | $7.65 B(+25.9%) |
| Sep 2024 | - | $6.08 B(-9.1%) |
| Jun 2024 | - | $6.68 B(+3.9%) |
| Mar 2024 | $28.06 B(+9.1%) | $6.43 B(-19.0%) |
| Dec 2023 | - | $7.94 B(+5.0%) |
| Sep 2023 | - | $7.56 B(+16.6%) |
| Jun 2023 | - | $6.49 B(+6.7%) |
| Mar 2023 | $25.73 B(-4.8%) | $6.08 B(-9.7%) |
| Dec 2022 | - | $6.74 B(+3.6%) |
| Sep 2022 | - | $6.50 B(+2.5%) |
| Jun 2022 | - | $6.34 B(-6.7%) |
| Mar 2022 | $27.04 B(+2.4%) | $6.80 B(-1.5%) |
| Dec 2021 | - | $6.90 B(+1.7%) |
| Sep 2021 | - | $6.79 B(+6.0%) |
| Jun 2021 | - | $6.40 B(-4.7%) |
| Mar 2021 | $26.41 B(-5.4%) | $6.72 B(+1.1%) |
| Dec 2020 | - | $6.64 B(-4.8%) |
| Sep 2020 | - | $6.98 B(+18.3%) |
| Jun 2020 | - | $5.90 B(-0.8%) |
| Mar 2020 | $27.92 B(+62.5%) | $5.95 B(-19.8%) |
| Dec 2019 | - | $7.41 B(+6.4%) |
| Sep 2019 | - | $6.97 B(-4.8%) |
| Jun 2019 | - | $7.31 B(-0.5%) |
| Mar 2019 | $17.18 B(+20.2%) | $7.35 B(+114.1%) |
| Dec 2018 | - | $3.43 B(+7.0%) |
| Sep 2018 | - | $3.21 B(-0.3%) |
| Jun 2018 | - | $3.22 B(-35.0%) |
| Mar 2018 | $14.29 B(-5.4%) | $4.95 B(+39.6%) |
| Dec 2017 | - | $3.54 B(-0.2%) |
| Sep 2017 | - | $3.55 B(+55.8%) |
| Jun 2017 | - | $2.28 B(-51.6%) |
| Mar 2017 | $15.11 B(+8.1%) | $4.71 B(+25.5%) |
| Dec 2016 | - | $3.75 B(-5.7%) |
| Sep 2016 | - | $3.98 B(+53.0%) |
| Jun 2016 | - | $2.60 B(-33.5%) |
| Mar 2016 | $13.97 B | $3.91 B(+10.0%) |
| Dec 2015 | - | $3.56 B(+9.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2015 | - | $3.25 B(-0.7%) |
| Jun 2015 | - | $3.27 B(-49.1%) |
| Mar 2015 | $17.44 B(+12.5%) | $6.43 B(+81.0%) |
| Dec 2014 | - | $3.55 B(-4.6%) |
| Sep 2014 | - | $3.73 B(+9.5%) |
| Jun 2014 | - | $3.40 B(-20.9%) |
| Mar 2014 | $15.50 B(-14.1%) | $4.30 B(+10.1%) |
| Dec 2013 | - | $3.90 B(+5.7%) |
| Sep 2013 | - | $3.69 B(+3.3%) |
| Jun 2013 | - | $3.58 B(-27.4%) |
| Mar 2013 | $18.05 B(+14.6%) | $4.93 B(+11.1%) |
| Dec 2012 | - | $4.43 B(+1.8%) |
| Sep 2012 | - | $4.36 B(+4.0%) |
| Jun 2012 | - | $4.19 B(-13.0%) |
| Mar 2012 | $15.76 B(+29.0%) | $4.81 B(+0.4%) |
| Dec 2011 | - | $4.80 B(+5.1%) |
| Sep 2011 | - | $4.57 B(+172.6%) |
| Jun 2011 | - | $1.67 B(-78.0%) |
| Mar 2011 | $12.22 B(+8.4%) | $7.63 B(+320.3%) |
| Dec 2010 | - | $1.82 B(+11.8%) |
| Sep 2010 | - | $1.62 B(+10.5%) |
| Jun 2010 | - | $1.47 B(-78.6%) |
| Mar 2010 | $11.27 B(-9.0%) | $6.85 B(+316.1%) |
| Dec 2009 | - | $1.65 B(+10.1%) |
| Sep 2009 | - | $1.50 B(+6.9%) |
| Jun 2009 | - | $1.40 B(-79.3%) |
| Mar 2009 | $12.39 B(+48.3%) | $6.77 B(+409.5%) |
| Dec 2008 | - | $1.33 B(-10.1%) |
| Sep 2008 | - | $1.48 B |
| Mar 2008 | $8.35 B(+15.3%) | - |
| Mar 2007 | $7.24 B(+1.2%) | - |
| Mar 2006 | $7.16 B(+4.1%) | - |
| Mar 2005 | $6.87 B(+8.4%) | - |
| Mar 2004 | $6.34 B(+5.0%) | - |
| Mar 2003 | $6.04 B(+4.2%) | - |
| Mar 2002 | $5.80 B(-13.2%) | - |
| Mar 2001 | $6.68 B(-1.4%) | - |
| Mar 2000 | $6.78 B | - |
FAQ
- What is Takeda Pharmaceutical Company Limited annual total expenses?
- What is the all time high annual total expenses for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited annual total expenses year-on-year change?
- What is Takeda Pharmaceutical Company Limited quarterly total expenses?
- What is the all time high quarterly total expenses for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited quarterly total expenses year-on-year change?
What is Takeda Pharmaceutical Company Limited annual total expenses?
The current annual total expenses of TAK is $28.06 B
What is the all time high annual total expenses for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high annual total expenses is $28.06 B
What is Takeda Pharmaceutical Company Limited annual total expenses year-on-year change?
Over the past year, TAK annual total expenses has changed by +$2.33 B (+9.07%)
What is Takeda Pharmaceutical Company Limited quarterly total expenses?
The current quarterly total expenses of TAK is $7.65 B
What is the all time high quarterly total expenses for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high quarterly total expenses is $7.94 B
What is Takeda Pharmaceutical Company Limited quarterly total expenses year-on-year change?
Over the past year, TAK quarterly total expenses has changed by +$1.57 B (+25.89%)